Acute Hepatitis B in a Patient with Antibody to Hepatitis B Surface Antigen who was Receiving Chemotherapy for Acute Myelogenous Leukemia with Cytarabine and Daunorubicin

Authors

Mehdi Dehghani Mehdi Dehghani  ORCID1,*
1Assistant Professor, Section of Hematology and Oncology, Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
*Corresponding Author: Department of Internal Medicine, Nemazee Hospital, Shiraz, Iran, [email protected]. Tel: +98-7116261089. Fax: +98-7116261089. Email: [email protected]

Shiraz E-Medical Journal:Vol. 9, issue 1; 42-44
Published online:Jan 01, 2008
Article type:Case Report
Received:May 01, 2005
Accepted:Sep 02, 2007
How to Cite:Dehghani M. Acute Hepatitis B in a Patient with Antibody to Hepatitis B Surface Antigen who was Receiving Chemotherapy for Acute Myelogenous Leukemia with Cytarabine and Daunorubicin. Shiraz E-Med J. 2008;9(1):. doi:

Abstract

Hepatitis B virus asymptomatic carriers should receive treatment in certain conditions, such as prior to chemotherapy and organ transplantation. In these groups interferon alpha has limited efficacy or is even contraindicated. In contrast, lamivudine is highly effective in both preventing of and treat- ment of HBV reactivation in these immunosuppressed patients. Prevention of reactivation has better results than treating reactivation.

Full Text

Full text is available in PDF

Copyright

© 2008, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

26
Mar
2016

Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review

Soheil Tavakolpour,
Seyed Moayed Alavian,
Shahnaz Sali

Tavakolpour S, Alavian SM, Sali S. Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review. Hepat Mon. 2016;16(4):e35810. doi: https://doi.org/10.5812/hepatmon.35810

4
Aug
2017

Risk of HBV Reactivation in Patients Infected with HBV/HCV Treated with DAA

Malgorzata Pawlowska,
Krzysztof Domagalski

Pawlowska M, Domagalski K. Risk of HBV Reactivation in Patients Infected with HBV/HCV Treated with DAA. Hepat Mon. 2017;17(8):e12317. doi: https://doi.org/10.5812/hepatmon.12317

30
Dec
2012

Management of Hepatitis B Virus Infection in Liver Transplantation Setting; The Rising Concerns and Growing Hopes, Report From 10th Congress of the Iranian Society for Organ Transplantation, 2011, Shiraz, Iran

Seyed Moayed Alavian,
Kamran B. Lankarani,
Mario Rizzetto,
Alfredo Marzano,
Mohsen Moghadami,
Saman Nik-Eghbolian
,et al.

Alavian SM, B. Lankarani K, Rizzetto M, Marzano A, Moghadami M, et al. Management of Hepatitis B Virus Infection in Liver Transplantation Setting; The Rising Concerns and Growing Hopes, Report From 10th Congress of the Iranian Society for Organ Transplantation, 2011, Shiraz, Iran. Hepat Mon. 2012;12(12):8094. doi: https://doi.org/10.5812/hepatmon.8094

30
Sep
2009

Poor Response to Treatment with Peg-IFN Containing Regimens in Patients Coinfected with Hepatitis B and Hepatitis C Virus

Serpil Erol,
Zulal Ozkurt,
Ahmet Ozbek,
Mehmet Parlak

Erol S, Ozkurt Z, Ozbek A, Parlak M. Poor Response to Treatment with Peg-IFN Containing Regimens in Patients Coinfected with Hepatitis B and Hepatitis C Virus. Hepat Mon. 2009;9(3):. doi:

17
Dec
2019
Evaluation of Occult Hepatitis B Infection in Individuals with Chronic Hepatitis C Before Treatment with Oral Direct-Acting Antivirals

Evaluation of Occult Hepatitis B Infection in Individuals with Chronic Hepatitis C Before Treatment with Oral Direct-Acting Antivirals

Nathalia Alves Araujo de Almeida,
José J. Barros,
Catarina Goes de Santana,
Natalia Spitz,
Leticia Bomfim Campos,
Marcia Amendola Pires
,et al.

de Almeida NAA, Barros JJ, de Santana CG, Spitz N, Campos LB, et al. Evaluation of Occult Hepatitis B Infection in Individuals with Chronic Hepatitis C Before Treatment with Oral Direct-Acting Antivirals. Hepat Mon. 2019;19(12):e92317. doi: https://doi.org/10.5812/hepatmon.92317

More by these authors

Mehdi DehghaniPubMedScholar
Share
Cited by
Metrics